Canada National Advisory Committee Publishes Recommendation for Use of Novavax's Nuvaxovid XBB.1.5 COVID-19 Vaccine
Canada National Advisory Committee Publishes Recommendation for Use of Novavax's Nuvaxovid XBB.1.5 COVID-19 Vaccine
Canada's National Advisory Committee on Immunization has published guidance on the use of Nuvaxovid XBB.1.5, a recombinant protein subunit COVID-19 vaccine, in Canada. The recommendations state that Nuvaxovid XBB.1.5 can be used in unvaccinated or previously vaccinated individuals aged 12 years and older.
This recommendation supports efforts to provide greater access to a non-mRNA protein-based COVID-19 vaccine option and could help achieve improved immunization rates. The vaccine has been distributed by the Public Health Agency of Canada across the regions, and provincial public health programs can advise on specific availabilities.
Data from clinical trials continue to show broad neutralization responses to currently circulating forward-drift variants including JN.1 and JN.4 for our protein-based non-mRNA COVID-19 vaccine, while maintaining a favorable side effect profile. Peer-reviewed real-world effectiveness data is being published that shows the immune responses seen in our trials translates into COVID-19 prevention in the real world.1
References:
1. Link-Gelles R, et al. Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024. MMWR. 2024; accessed online February 28, 2024, at https://www.cdc.gov/mmwr/volumes/73/wr/mm7304a2.htm?s_cid=mm7304a2_w
Canada's National Advisory Committee on Immunization has published guidance on the use of Nuvaxovid XBB.1.5, a recombinant protein subunit COVID-19 vaccine, in Canada. The recommendations state that Nuvaxovid XBB.1.5 can be used in unvaccinated or previously vaccinated individuals aged 12 years and older.
加拿大全國免疫諮詢委員會發布了 指導 關於加拿大使用重組蛋白亞單位 COVID-19 疫苗 Nuvaxovid XBB.1.5 的情況。建議指出，Nuvaxovid XBB.1.5可用於未接種疫苗或之前接種過疫苗的12歲及以上的個人。
This recommendation supports efforts to provide greater access to a non-mRNA protein-based COVID-19 vaccine option and could help achieve improved immunization rates. The vaccine has been distributed by the Public Health Agency of Canada across the regions, and provincial public health programs can advise on specific availabilities.
該建議支持爲非mRNA蛋白質的 COVID-19 疫苗選擇提供更多機會的努力，並可能有助於提高免疫率。該疫苗已由加拿大公共衛生局在各地區分發，省級公共衛生計劃可以就具體的可用性提供建議。
Data from clinical trials continue to show broad neutralization responses to currently circulating forward-drift variants including JN.1 and JN.4 for our protein-based non-mRNA COVID-19 vaccine, while maintaining a favorable side effect profile. Peer-reviewed real-world effectiveness data is being published that shows the immune responses seen in our trials translates into COVID-19 prevention in the real world.1
臨床試驗數據繼續顯示，我們的蛋白基非mRNA COVID-19 疫苗對當前流行的前向漂移變體（包括JN.1和JN.4）具有廣泛的中和反應，同時保持了良好的副作用特徵。經過同行評審的真實世界有效性數據正在發佈中，這些數據顯示我們在試驗中看到的免疫反應轉化爲現實世界中 COVID-19 的預防。1
References:
參考文獻：
1. Link-Gelles R, et al. Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024. MMWR. 2024; accessed online February 28, 2024, at https://www.cdc.gov/mmwr/volumes/73/wr/mm7304a2.htm?s_cid=mm7304a2_w
1。Link-Gelles R 等人。2023—2024 年更新版（單價 XBB.1.5）COVID-19 疫苗對可歸因於免疫功能正常的成年人中共同循環的 Omicron 變體的症狀 SARS-CoV-2 感染的有效性的早期估計——增加社區參與測試計劃的機會，美國，2023 年 9 月至 2024 年 1 月。MMWR. 2024；2024 年 2 月 28 日在線訪問，網址爲 https://www.cdc.gov/mmwr/volumes/73/wr/mm7304a2.htm?s_cid=mm7304a2_w
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧